Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

The designation will provide Lundbeck with the possibility of rolling reviews and detailed guidance to streamline the drug ...

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

A downtown Auburn brewpub has announced that it is closing temporarily due to one of its owners having a terminal illness.

Alterity Therapeutics Limited (market cap: $40 million), a pharmaceutical company specializing in the development of therapeutic drugs, has secured A$40 million in funding to advance the development ...

Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders –– Capital raising was strongly supported by domestic and ...

A new electrical stimulation therapy for spinal muscle atrophy (SMA) has shown promise in reactivating motor neurons and ...

An incredible life of extraordinary kindness, service, and humble achievement came to a close Feb. 1, 2025 with the passing of Diane Eastman Jones of North Hampton, N.H., from complications ...

Alterity Therapeutics Ltd. reported positive top-line phase II results for lead candidate ATH-434 for treating multiple system atrophy, a rare neurological disorder similar to Parkinson's disease.

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) were trading at $55, up $29.28, or 113%, on positive interim data from the phase Ib acute hemodynamic trial of its lead product candidate, TX-45.

Maxim analyst Jason McCarthy raised the firm’s price target on Alterity Therapeutics (ATHE) to $12 from $8 and keeps a Buy rating on the shares ...